Paltusotine

Paltusotine is a selective somatostatin receptor type 2 (SST2) agonist in development by Crinetics Pharmaceuticals for the treatment of acromegaly and certain neuroendocrine tumors. It is a small molecule delivered orally.^[1][2][3][4]

Paltusotine

Legal status
Legal status	Investigational
Identifiers
IUPAC name 3-[4-(4-Amino-1-piperidinyl)-3-(3,5-difluorophenyl)-6-quinolinyl]-2-hydroxybenzonitrile
CAS Number	2172870-89-0
PubChem CID	134168328
ChemSpider	81367268
UNII	F2IBD1GMD3
Chemical and physical data
Formula	C27H22F2N4O
Molar mass	456.497 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1CN(CCC1N)C2=C3C=C(C=CC3=NC=C2C4=CC(=CC(=C4)F)F)C5=CC=CC(=C5O)C#N
InChI InChI=1S/C27H22F2N4O/c28-19-10-18(11-20(29)13-19)24-15-32-25-5-4-16(22-3-1-2-17(14-30)27(22)34)12-23(25)26(24)33-8-6-21(31)7-9-33/h1-5,10-13,15,21,34H,6-9,31H2 Key:GHILNKWBALQPDP-UHFFFAOYSA-N